Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
- Julia J Scarisbrick
Future Oncol 2017 Aug 14. Epub 2017 Aug 14.
Dermatology - University Hospitals Birmingham NHS Foundation Trust, University Hospital Birmingham, Birmingham, B15 2TH, UK.
CD30-positive primary cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides, anaplastic large-cell lymphoma and lymphomatoid papulosis type A. Brentuximab vedotin (BV) consists of an antibody targeting CD30 with a protease-cleavable linker to vedotin. CD30 binding allows internalization of BV inducing cell-cycle arrest and apoptosis. Read More